Enanta Pharmaceuticals Advances Zelicapavir into Registrational Phase 2b/3 Clinical Trial
Enanta Pharmaceuticals is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration. The Phase 2b portion of the trial will confirm the treatment effect with topline data expected in 2027. Enanta also announced plans to initiate a Phase 2b clinical trial of zelicapavir in pediatric patients with RSV, with topline data expected in 2027.
Trade with 70% Backtested Accuracy
Analyst Views on ENTA
About ENTA
About the author
Enanta Pharmaceuticals Advances Zelicapavir Clinical Trials for RSV
- Clinical Trial Advancement: Enanta Pharmaceuticals announced the initiation of a registrational Phase 2b/3 clinical trial for Zelicapavir in high-risk adults with RSV, set to begin in Q4 2026, with topline data expected in 2027, marking a significant step forward in RSV treatment development.
- Pediatric Trial Plans: The company also plans to launch a Phase 2b clinical trial for pediatric patients with RSV in Q3 2026, with topline data anticipated in 2027, potentially providing a treatment option for children and expanding Zelicapavir's market application.
- Significant Market Opportunity: Enanta estimates that an oral RSV antiviral for children and all high-risk adults represents a global market opportunity exceeding $2 billion, with a potential addressable population of over 3 million patients in the U.S., highlighting Zelicapavir's commercial potential.
- Safety and Efficacy: Previous trials demonstrated Zelicapavir's significant efficacy in high-risk adults, reducing the time to complete resolution of symptoms by 6.7 days and achieving a hospitalization rate of 0%, establishing a strong foundation for its future market introduction.
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 for Chronic Urticaria
- Trial Initiation: Enanta Pharmaceuticals has announced the dosing of the first participant in a Phase 1 clinical trial for EDP-978, an oral once-daily KIT inhibitor aimed at treating chronic urticaria and other mast cell-driven diseases, marking a significant step in advancing its immunology program into clinical development.
- Participant Recruitment: The trial is expected to enroll approximately 98 healthy adult volunteers aged 18 to 65 years to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EDP-978, providing critical data for future treatment options.
- Data Release Expectations: Enanta anticipates reporting topline data in Q4 2026, including effects on biomarkers such as serum tryptase, which will offer important insights into the activity of EDP-978 and address the unmet medical needs in chronic urticaria treatment.
- Market Potential: Chronic urticaria significantly impacts patients' quality of life, with many existing therapies proving ineffective; thus, the development of EDP-978 not only aims to fill this medical gap but also presents substantial market opportunities and potential revenue growth for Enanta.
Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
- FDA Approval: Agios Pharmaceuticals announced that its drug Aqvesme received FDA approval, becoming the only treatment for non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance its market competitiveness.
- Stock Price Rebound: Following the FDA approval announcement, AGIO's stock surged 18.6% to $29.17, with trading volume exceeding average levels, indicating strong investor confidence in the company's prospects.
- Earnings Outlook: Although the upcoming quarterly report is expected to show a loss of $1.96 per share, a 12.6% year-over-year decline, revenues are projected at $11.14 million, reflecting a 3.8% increase from the previous year, demonstrating resilience amid challenges.
- Market Attention: AGIO's consensus EPS estimate has remained unchanged over the past 30 days, and despite the stock's rise, investors should monitor future earnings estimate revisions to assess whether the stock can maintain its upward momentum.
JP Morgan Begins Coverage of Enanta Pharmaceuticals (ENTA) with Positive Outlook
JP Morgan Coverage Initiation: On November 14, 2025, JP Morgan began coverage of Enanta Pharmaceuticals (NasdaqGS:ENTA) with an "Overweight" recommendation, projecting a 62.04% upside based on an average one-year price target of $19.53/share.
Projected Revenue and EPS: Enanta Pharmaceuticals is expected to see a significant increase in annual revenue, projected at $834 million, which represents a 1,186.29% growth, alongside a projected non-GAAP EPS of 10.27.
Institutional Ownership Trends: There are currently 275 funds reporting positions in Enanta Pharmaceuticals, with a slight increase in ownership and a total of 20,591K shares held by institutions, reflecting a 1.16% rise over the last three months.
Shareholder Activity: Notable changes in shareholder positions include Janus Henderson Group increasing its stake by 111.20%, while Millennium Management reduced its holdings by 53.85%, indicating varied strategies among institutional investors.
Microsoft Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday
Analyst Ratings Overview: Top Wall Street analysts have updated their ratings on several companies, including Microsoft, Enanta Pharmaceuticals, and Polaris Inc.
Microsoft Corp Rating: Baird analyst William Power initiated coverage on Microsoft with an Outperform rating and a price target of $600, while shares closed at $503.29.
Enanta Pharmaceuticals Rating: JP Morgan analyst Anupam Rama initiated coverage on Enanta Pharmaceuticals with an Overweight rating and a price target of $17, with shares closing at $11.72.
Polaris Inc Rating: Loop Capital analyst Brandon Rolle initiated coverage on Polaris with a Hold rating and a price target of $59, while shares closed at $64.82.
Enanta Shares Climb Following J.P. Morgan's Overweight Rating on RSV Treatment
Stock Performance: Enanta Pharmaceuticals' shares rose after J.P. Morgan initiated coverage with an Overweight rating, highlighting the potential of their experimental RSV therapy, zelicapavir.
Analyst Projections: Analyst Anupam Rama set a price target of $17 per share, forecasting over $1.5 billion in peak global sales for zelicapavir, with significant contributions expected from the U.S. market.
Clinical Trial Success: The stock's surge followed positive mid-stage trial results for zelicapavir, which is designed for high-risk outpatient adults with acute RSV, indicating strong market potential.
Partnership Opportunities: Enanta is likely to seek partnerships for zelicapavir, which could lead to substantial non-dilutive financing, with peak net global revenue estimates exceeding $300 million.
Enanta Pharmaceuticals Advances Zelicapavir Clinical Trials for RSV
- Clinical Trial Advancement: Enanta Pharmaceuticals announced the initiation of a registrational Phase 2b/3 clinical trial for Zelicapavir in high-risk adults with RSV, set to begin in Q4 2026, with topline data expected in 2027, marking a significant step forward in RSV treatment development.
- Pediatric Trial Plans: The company also plans to launch a Phase 2b clinical trial for pediatric patients with RSV in Q3 2026, with topline data anticipated in 2027, potentially providing a treatment option for children and expanding Zelicapavir's market application.
- Significant Market Opportunity: Enanta estimates that an oral RSV antiviral for children and all high-risk adults represents a global market opportunity exceeding $2 billion, with a potential addressable population of over 3 million patients in the U.S., highlighting Zelicapavir's commercial potential.
- Safety and Efficacy: Previous trials demonstrated Zelicapavir's significant efficacy in high-risk adults, reducing the time to complete resolution of symptoms by 6.7 days and achieving a hospitalization rate of 0%, establishing a strong foundation for its future market introduction.
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 for Chronic Urticaria
- Trial Initiation: Enanta Pharmaceuticals has announced the dosing of the first participant in a Phase 1 clinical trial for EDP-978, an oral once-daily KIT inhibitor aimed at treating chronic urticaria and other mast cell-driven diseases, marking a significant step in advancing its immunology program into clinical development.
- Participant Recruitment: The trial is expected to enroll approximately 98 healthy adult volunteers aged 18 to 65 years to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EDP-978, providing critical data for future treatment options.
- Data Release Expectations: Enanta anticipates reporting topline data in Q4 2026, including effects on biomarkers such as serum tryptase, which will offer important insights into the activity of EDP-978 and address the unmet medical needs in chronic urticaria treatment.
- Market Potential: Chronic urticaria significantly impacts patients' quality of life, with many existing therapies proving ineffective; thus, the development of EDP-978 not only aims to fill this medical gap but also presents substantial market opportunities and potential revenue growth for Enanta.
Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
- FDA Approval: Agios Pharmaceuticals announced that its drug Aqvesme received FDA approval, becoming the only treatment for non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance its market competitiveness.
- Stock Price Rebound: Following the FDA approval announcement, AGIO's stock surged 18.6% to $29.17, with trading volume exceeding average levels, indicating strong investor confidence in the company's prospects.
- Earnings Outlook: Although the upcoming quarterly report is expected to show a loss of $1.96 per share, a 12.6% year-over-year decline, revenues are projected at $11.14 million, reflecting a 3.8% increase from the previous year, demonstrating resilience amid challenges.
- Market Attention: AGIO's consensus EPS estimate has remained unchanged over the past 30 days, and despite the stock's rise, investors should monitor future earnings estimate revisions to assess whether the stock can maintain its upward momentum.
JP Morgan Begins Coverage of Enanta Pharmaceuticals (ENTA) with Positive Outlook
JP Morgan Coverage Initiation: On November 14, 2025, JP Morgan began coverage of Enanta Pharmaceuticals (NasdaqGS:ENTA) with an "Overweight" recommendation, projecting a 62.04% upside based on an average one-year price target of $19.53/share.
Projected Revenue and EPS: Enanta Pharmaceuticals is expected to see a significant increase in annual revenue, projected at $834 million, which represents a 1,186.29% growth, alongside a projected non-GAAP EPS of 10.27.
Institutional Ownership Trends: There are currently 275 funds reporting positions in Enanta Pharmaceuticals, with a slight increase in ownership and a total of 20,591K shares held by institutions, reflecting a 1.16% rise over the last three months.
Shareholder Activity: Notable changes in shareholder positions include Janus Henderson Group increasing its stake by 111.20%, while Millennium Management reduced its holdings by 53.85%, indicating varied strategies among institutional investors.
Microsoft Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday
Analyst Ratings Overview: Top Wall Street analysts have updated their ratings on several companies, including Microsoft, Enanta Pharmaceuticals, and Polaris Inc.
Microsoft Corp Rating: Baird analyst William Power initiated coverage on Microsoft with an Outperform rating and a price target of $600, while shares closed at $503.29.
Enanta Pharmaceuticals Rating: JP Morgan analyst Anupam Rama initiated coverage on Enanta Pharmaceuticals with an Overweight rating and a price target of $17, with shares closing at $11.72.
Polaris Inc Rating: Loop Capital analyst Brandon Rolle initiated coverage on Polaris with a Hold rating and a price target of $59, while shares closed at $64.82.
Enanta Shares Climb Following J.P. Morgan's Overweight Rating on RSV Treatment
Stock Performance: Enanta Pharmaceuticals' shares rose after J.P. Morgan initiated coverage with an Overweight rating, highlighting the potential of their experimental RSV therapy, zelicapavir.
Analyst Projections: Analyst Anupam Rama set a price target of $17 per share, forecasting over $1.5 billion in peak global sales for zelicapavir, with significant contributions expected from the U.S. market.
Clinical Trial Success: The stock's surge followed positive mid-stage trial results for zelicapavir, which is designed for high-risk outpatient adults with acute RSV, indicating strong market potential.
Partnership Opportunities: Enanta is likely to seek partnerships for zelicapavir, which could lead to substantial non-dilutive financing, with peak net global revenue estimates exceeding $300 million.
